Zydus Initiates Adaptive P-I/II Clinical Study Evaluating its ZyCoV-D Against COVID-19 in India

Shots:

Zydus has commenced the adaptive P-I/II human clinical trials of its plasmid DNA vaccine, ZyCoV-D and reported its first human dosing
The Adaptive P-I/II dose escalation study will assess the safety, tolerability, and immunogenicity of the vaccine in ~1000 candidates across multiple clinical sites in India. The company has already manufacture clinical GMP batches of the vaccine candidate for the clinical trials

ZyCoV-D has demonstrated a strong immune response and a high level of neutralizing Abs in its preclinical studies

Click here to read full press release/ article | Ref: Zydus | Image: The Quint